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DRUGS AND THE GASTROINTESTINAL TRACT 
 
The subjects covered are the agents used for the control of acidity, prokinetics (which make 
the gut work faster) and anti-emetic (drugs that prevent nausea and vomiting).  The agents 
used to treat diarrhoea, constipation and irritable bowel syndrome are also considered.   
Irritable bowel syndrome is fluctuations between diarrhea and constipation. Finally, drugs for 
inflammatory bowel disease are discussed. 
  
16.1. AGENTS TO CONTROL ACIDITY 
 
Dyspepsia (abdominal discomfort) is often triggered by particular foods (spicy, high fibre, 
fatty) or by eating too quickly or overeating.  Heartburn (pyrosis) is painful, burning 
sensation in the throat (oesophagus), which is caused by the back-up of acid from stomach 
into the oesophagus leading to heartburn.  Dyspepsia and heartburn are treated mainly with 
antacids, and if serious and ongoing, with proton pump inhibitors, and sometimes histamine 
H2-receptor antagonists.   
 
In gastroesophageal reflux disease (GERD, or gastrooesophageal to give GORD) there is 
heartburn and regurgitation.  In GERD, the lower oesophageal sphincter is either weakened 
or opens too often.  The sphincter defect can be caused by a hiatus hernia, obesity or 
pregnancy.  If untreated, GERD can lead to cancers of the oesophagus.  GERD is treated with 
antacids, proton pump inhibitors, and histamine H2-receptor antagonists.   
 
Peptic ulcers are due to an imbalance between mucosal defence factors and aggressive 
factors leading to excessive acid production, as discussed in Section 7.6.1.  Helicobacter 
pylori infection is commonly associated with these ulcers.  Treatment is with antibiotics to 
overcome the infection and with proton pump inhibitors to overcome the excessive acidity.   
 
Ulcers can also be induced by the Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) that are 
non-selective inhibitors of cyclooxygenase (COX) (e.g. aspirin).  The ulcers are due to the 
removal of the cytoprotective prostaglandins.  The treatment of NSAIDs-induced ulcers is 
proton pump inhibitors or misoprostol. 
 
 16.1.1 Antacids 
Anti-acids (which are alkaline solutions) can be used to neutralise the acid in the stomach.  





hydroxides provide a relatively fast and sustained neutralising capacity.  Carbonates and 
bicarbonates also neutralise acid.   
 
Mylanta is a mixture of aluminium hydroxide and magnesium hydroxide.   
 
Gaviscon is a mixture of calcium carbonate, sodium bicarbonate and alignate, which is a 
viscous gum.  Alignate helps protective mucus stick to the oesophagus, and this prevent acid 
damage.   
 
As Mylanta and Gaviscone are available over-the-counter, it indicates that they are relatively 
safe agents.  They are also cheap, compared to visiting a doctor and paying for a prescription.  
Antacids are cleared from stomach in about 30 minutes, which means that they may need to 
be taken frequently.   
 
Antacids will increase the pH of the stomach, and altering gastric pH can affect dissolution, 
absorption and bioavailability of several drugs.  In order to prevent this problem, it is best to 
avoid concurrent administration of antacids and other drugs.  The suggestion is that there 
should be a two hour gap between taking antacids and other drugs.   
 
With normal renal function, the modest accumulation of Al
3+
 from aluminium hydroxide is 
not a problem.  However, in renal insufficiency, the increase levels of Al
3+
 can contribute to 
osteoporosis and proximal myopathy.   
 
Antacids are used in the treatment of dyspepsia, heartburn, GERD, peptic ulcers and 
NSAIDs-induced ulcers.  Antacids only relieve the symptoms; they do nothing to the 
underlying conditions. 
 
 16.1.2 Proton pump inhibitors (PPIs) and antibiotics for Helicobacter pylori 
The most effective way to overcome excess acid, being produced from the parietal cells of 
the stomach, is to use proton pump inhibitors.  This is because regardless of what is 
stimulating the acid secretion (histamine, gastrin and acetylcholine), inhibiting the proton 
pump will inhibit acid secretion.  This makes the proton pump inhibitors the most effective 
inhibitors of acid secretion.   
 
Omeprazole is the prototype proton pump inhibitor but there are other –prazoles in clinical 
use.  The proton pump inhibitors are prodrugs, requiring activation in an acidic environment.  
To avoid activation of the omeprazole by the acid in the oesophagus and stomach, 
omeprazole is supplied as enteric-coated granules that dissolve only at an alkaline pH, which 
limits absorption to the intestine.  Omeprazole is then carried in the blood stream until it is 
activated in the acid environment of the stomach.   
 
The proton pump inhibitors inhibit the activity of some cytochrome P45O enzymes, and may 
decrease the clearance of benzodiazepines, phenytoin and warfarin, which will increase the 
concentration and increase the toxicity of these medicines.  Proton pump inhibitors are used 
in the treatment of GERD and peptic ulcers, and in the prevention of NSAIDs-induced ulcers. 
 
Up to 90% of peptic ulcers may be associated with Helicobacter pylori infections of the 
stomach leading to increased stimulation of acid secretion.  H. pylori are Gram-negative rods.  
Unfortunately, single antibiotic regimens are ineffective as resistance has developed to H. 
pylori. Indeed, antibiotic resistance is preventing the elimination of H. pylori.  The preferred 
combination of antibiotics used to kill H. pylori is amoxicillin and clarithromycin.  These 
antibiotics are generally used in combination with a proton pump inhibitor.  Besides reducing 
the acid secretion, the proton pump inhibitor enhances the effectiveness of pH-dependent 
antibiotics such as amoxicillin or clarithromycin. 
 
 16.1.3 Histamine H2 receptor antagonists 
Histamine H2 receptor antagonists have previously been discussed (Chapter 16.3).  An 
example of an H2-receptor antagonist is ranitidine.  Ranitidine is a relatively safe drug and is 
available over-the-counter in low doses.  As histamine acting at the H2-receptor is only one of 
the stimulants of acid secretion, H2-receptor antagonists are only effective against this 
component.  There are other stimulants of gastric secretion e.g. gastrin and acetylcholine, and 
H2-receptor antagonists do not inhibit this secretion whereas proton pump inhibitors do.  
Thus, proton pump inhibitors are often preferred to H2-receptor antagonists in peptic acidity 
conditions.  H2-receptor antagonists can be used for dyspepsia, heartburn, and GERD. 
 
 16.1.4 Misoprostol  
Misoprostol has previously been discussed (Chapter 17.3.4).  Misoprostol is a selective 
agonist at prostaglandin EP receptors.  Misoprostol is active after oral administration, and is 
long lasting.  Misoprostol is an effective inhibitor of acid secretion.  The most frequent side 
effect with misoprostol is diarrhoea, which occurs in about 30% of patients.  The mechanism 
of the diarrhea is prostaglandin EP receptor-mediated stimulation of gut motility.  
Misoprostol also cause EP-receptor-mediated contractions of the uterus. Thus, misoprostol is 
contraindicated during pregnancy because it can cause abortion.  Misoprostol is used to 
prevent mucosal injury caused by NSAIDs. 
 
 16.1.5 Sucralfate 
After acid has damaged the lining of the intestine, pepsin can digest the mucosal proteins, and 
this contributes to mucosal erosion and ulceration.  In an acidic environment, sucralfate 
produces a viscous, sticky gel.  This gel sticks to ulcers to inhibit digestion of mucosal 
proteins.  Antacids will prevent sucralfate from working, and should not be taken at the same 
time.  By lining the intestine, sucralfate can prevent the absorption of some drugs (e.g. 
phenytoin, digoxin).  To avoid this, sucralfate should be taken after other drugs.  Sucralfate is 
occasionally used to treat ulcers. 
 
16.2 PROKINETICS AND EMETICS 
 
 16.2.1 Introduction to prokinetics 
Prokinetics enhance gastrointestinal motility and transit of material in gastrointestinal tract.  
Heartburn is due to the backup of acid from the stomach and oesophagus.  The most common 
cause of heartburn is Gastroesophageal reflux disease (GERD or GORD).  In GERD there 
is either a weakened lower oesophageal sphincter or the sphincter relaxes too frequently.  In 
GERD, prokinetics prevent the heartburn by increase the motility in the oesophagus.   
 
Gastroparesis is severely impaired emptying of stomach not caused by obstruction.  The 
usual cause of gastroparesis is the loss of neural control as a result of diabetes.  In 
gastroparesis, prokinetics increase the motility in the stomach, and this increases stomach 
emptying.   
 
Irritable Bowel Syndrome (IBS) is intermittent cramps and constipation, with alternating 
periods of diarrhoea.  Prokinetics are used in the constipation associated with irritable bowel 
syndrome. 
 
 16.2.2 Prokinetic agents 
The contraction phase of peristalsis is due to release of acetylcholine from excitatory motor 
neurones.  Prokinetic agents modify this release of acetylcholine.  For instance, dopamine 
acts at D2-receptors to inhibit the release of acetylcholine from the enteric nervous system.  
Antagonists at D2-receptors will prevent this effect of dopamine, to increase the release of 
acetylcholine and increase gut motility.   
 
Domperidone is a selective dopamine D2-receptor antagonist that prevents the inhibitory 
effect of dopamine on acetylcholine release, which leads to an increased release of 
acetylcholine locally, which is prokinetic.  Domperidone is used in GERD and gastroparesis. 
 
5-Hydroxytryptamine (5-HT), acts at the 5-HT4 receptor, to stimulate the enteric nervous 
system.   
 
Metoclopramide is prokinetic by combining these two actions.  Thus, metoclopramide acts 
as an antagonist at dopamine D2-receptors, and an agonist at 5-HT4-receptors, to stimulate the 
gastrointestinal tract.  Metoclopramide is used in the treatment of GERD and gastroparesis. 
  16.2.3 Emesis with cytotoxic drugs and drugs for 
One of the most serious causes of nausea and emesis (vomiting) is cytotoxic drugs (drugs that 
kill cells), such as the anti-cancer drugs.  Some cytotoxic drugs are irritants to the gastro-
intestinal tract, and this irritation involves 5-HT3 receptors (Figure 16.1). 
 
The other route to nausea and vomiting with cytotoxic drugs is when they are carried in the 
blood, to the chemoreceptor trigger zone in the area postrema of the central nervous system.  
There is also a neural input after gastrointestinal irritation to the chemoreceptor trigger zone.  
The chemoreceptor trigger zone or emetic centre has 5-HT3-receptors, dopamine D2 
receptors, and muscarinic M1-receptors (Figure 16.1), and consequently drugs that act at 
these receptors can modify nausea and vomiting. 
 
 
Figure 16.1 Nausea and vomiting with cytotoxic drugs (Copyright QUT, Sheila Doggrell) 
 
The 5-HT3-receptor antagonists, the –etrons, such as ondansetron (prototype) act at 
centrally- and peripherally 5-HT3 receptors to inhibit emesis.  The –etrons, such as 
ondansetron, are the most effective agents for treating chemotherapy-induced nausea and 
vomiting, but they are not effective in motion sickness, which involves a different pathway. 
 
The dopamine D2-receptor antagonists, prochlorperazine and metoclopramide, act as 
antagonists at the dopamine D2-receptors in the chemoreceptor trigger zone to inhibit 
cytotoxic-induced emesis.  These drugs used to be standard treatment for cytotoxic-induced 
emesis, but their use is declining as they are less effective than the 5-HT3-receptor 
antagonists.   
 
Prochlorperazine and metoclopramide are also used in the nausea and vomiting associated 
with pregnancy (morning sickness), where the underlying pathway remains to be clarified. 
 
Substance P is a peptide neurotransmitter in the central nervous system that acts at NK1-
receptors.  By stimulating NK-receptors, substance P has a role in emetic pathways, 
especially the emesis associated with chemotherapy.  Apepitant is an antagonist at NK1-
receptors used to control chemotherapy-induced vomiting.  Apepitant is not usually used as 
the first choice in preventing the emesis associated with chemotherapy, but can be used in 
combination with ondansetron.  Thus, when ondansetron is not effective alone, the addition 
of apepitant can increase the ability to inhibit the emesis caused by chemotherapy.   Apepitant 
is metabolised by CYP3A4, and consequently can be involved in interactions with numerous 
drugs. 
 
The glucocorticoids, especially dexamethasone, are used as anti-emetics to prevent emesis 
with cytotoxic drugs.  The anti-emetic properties of the glucocorticoids were a seredipitous 
discovery.  Thus, when dexamethasone was being used in chemotherapy, it was notices that 
there was less nausea and vomiting.  As it was a chance discovery rather than a drug designed 
for specific target, the mechanism behind the anti-emetic effect of dexamethasone is not 
clear.  The mechanism may be related to inhibition of the synthesis of prostaglandin E2, as 
PGE2 probably has a role on emesis.  Dexamethasone is not generally used alone as an 
antiemetic, but is used with other antiemetics. 
 
 16.2.4 Motion sickness and drugs for 
Drugs that are effective in the treatment of cytotoxic-induced emesis are not effective in 
motion sickness, indicating a different pathway is involved.  Motion is monitored by the inner 
ear (the vestibular system), which has an input into the cerebellum, where histamine H1-
receptors and muscarinic M receptors are involved in controlling nausea and vomiting 
(Figure 16.2). 
 
Figure 16.2 Motion sickness (Copyright QUT, Sheila Doggrell) 
 
Thus, drugs that act at histamine H1 receptors or muscarinic receptor can modify motion 
sickness. The histamine H1-receptor antagonist promethazine crosses the blood-brain barrier 
to act at cerebellum histamine H1-receptors to inhibit motion sickness.  Promethazine also act 
as an antagonist at the cholinergic muscarinic receptors, which may contribute to 
effectiveness in preventing motion sickness. 
 
The muscarinic receptor antagonist scopolamine is non-selective.  Scopolamine crosses 
blood-brain barrier to act at the cerebellum M-receptor to inhibit motion sickness.  
Scopolamine is used as a transdermal patch to prevent motion sickness. 
 
 16.2.5 Post-operative emesis 
Some of the drugs used for cytotoxic drug-induced or motion sickness-induced emesis are 
also useful in post-operative emesis.  Thus, in post-operative emesis, the dopamine D2 
receptor antagonists (prochlorperazine, metoclopramide, the histamine H1-receptor antagonist 
promethazine, the 5-HT3-receptor antagonists (the –etrons, such as ondansetron) , and the 
muscarinic receptor antagonist scopolamine can all be useful.  
 
16.3. AGENTS USED FOR DIARRHEA, CONSTIPATION, AND IRRITABLE 
BOWEL SYNDROME 
 
Diarrhoea usually results from enteric infection and is short-lived and self-limiting, and does 
not usually require drug treatment.  Other conditions that cause diarrhoea include 
malabsorption, which is associated with lactose intolerance and gluten malabsorption.  
Inflammatory bowel disease and immune disease are also causes of diarrhea, and these 
conditions require treatment.   
 
Constipation is defined as having less than 3 stools per week.  In constipation, the colon is 
absorbing too much water due to slow movement through colon.   
 
Irritable Bowel Syndrome (IBS) is intermittent cramps and constipation, with alternating 
periods of diarrhoea.  Thus, the drugs to treat diarrhoea and constipation are used in the 
treatment of irritable bowel syndrome. 
 
 16.3.1 Treatment for diarrhea 
In the treatment of diarrhea, the replacement of fluids and electrolytes is a common treatment.  
In severe, prolonged bacterial infections, anti-bacterial drugs may be used. 
 
When people abuse the opioid heroin, they become constipated.  When the opioid morphine 
is used to relieve pain, it also causes constipation.  Heroin and morphine stimulates opioid -
receptors to decrease intestinal motility, which leads to increased absorption of water from 
the colon, and to constipation.  This adverse effect in people with normal gut function has 
been used to develop an opioid agent suitable for use in diarrhea.   
 
This agent is loperamide, which stimulates the gastrointestinal tract -receptors to be anti-
diarrheal in subjects with diarrhea.  Loperamide does not have any potential to be abused, as 
it is a poor penetrant of the central nervous system.  Also, there are no central nervous side 
effects with loperamide.  Loperamide is used in most forms of diarrhoea and in the diarrhea 
part of irritable bowel syndrome.  
 
 16.3.2 Treatment for constipation 
The first treatment for constipation is lifestyle changes such as having a diet rich in fibre, 
decreasing the dietary fat intake, and increasing the intake of fluids but these fluids should 
not be diuretics as they promote water loss from the body.  Daily exercise also stimulates 
peristalsis to overcome constipation. 
 
In terms of agents used to overcome constipation, the old remedy of castor oil is effective but 
unpleasant, and potentially toxic, and therefore rarely used these days.  Alternatives include 
bulk-forming laxatives, faecal softening agents, irritant laxatives and osmotic laxatives.   
 
Dietary fibre is resistant to enzymatic degradation and presented to colon unchanged, and 
thus increasing bulk stimulates peristalsis.  Bulk-forming laxatives mimic this effect.  
Methylcellulose (sold as Citrucel) is poorly fermented.  Poorly fermented fibre attracts water 
to increase stool bulk, which stimulates peristalsis and eases movement along the 
gastrointestinal tract.  Bulk-forming laxatives are commonly used to prevent constipation in 
subjects prone to constipation. 
 
Another example of a bulk-forming laxative is the commonly used psyllium husk.  Psyllium 
husk is derived from the plantago seed and is in many commercial products for constipation 
(as Metamucil).  It is fermented by the colonic bacteria to increase the bulk in the colon, and 
stimulate peristalsis.  The fermentation also produces short chain fatty acids, which stimulate 
motility in the gastrointestinal tract (are prokinetic).   
 
The faecal softening agents include docusate and liquid paraffin.  Docusate acts like a 
detergent to allow water and fatty substances to mix with faecal material to soften it, and 
make it easier to pass stools.  After the oral administration of docusate, there is an excretion 
of stools in 1-3 days.  For a faster excretion, rectal administration of docusate can be used, 
and gives excretion of stools in 15 minutes. 
 
Liquid paraffin is not dangerous after oral administration, as the absorption is minimal.  The 
liquid paraffin stays in the tract, and coats stools to prevent loss of water.  The major problem 
with using liquid paraffin as a faecal softening agent is that it can prevent the absorption of 
fat soluble vitamins (A, D, E and K), which will dissolve in the liquid paraffin and be 
excreted. 
 
Agents that stimulate or irritate the colon to cause contraction include bisacodyl and 
senna.  By stimulating colon contractions, bisacodyl and senna cause bowel evacuation in 6 
to 12 hours.  The faecal-softening agents and irritant laxatives are used in constipation. 
 
The osmotic laxatives are poorly absorbed, and draw water toward them by osmosis.  
Subsequently, the osmotically-mediated water retention stimulates peristalsis.  Examples of 
osmotic laxatives include glycerol, certain salts, and lactulose.  Glycerol is an osmotic 
laxative, which is used rectally.  After rectal administration, glycerol stimulates a bowel 
movement in an hour.  Glycerol is used in constipation and constipation associated with 
irritable bowel syndrome. 
 
The salts include milk of magnesia and Epsom salts.  Lactulose is a non-digestible 
carbohydrate.  Both salts and lactulose are taken orally, and in a low dose are laxative, but at 
high dose are cathartic (uncontrollable stools).   As laxatives, the salts work in 6 to 8 hours, 
lactulose takes longer, 24 to 48 hours.   
 
 16.3.3 Opioid-induced constipation 
The opioids e.g. morphine, are commonly used in the treatment of severe pain or pain 
associated with terminal disease.  The analgesia is due to stimulation of opioid µ-receptors in 
the central nervous system.  However stimulation of opioid µ-receptors on the gastrointestinal 
tract leads to constipation.  Thus, constipation is a common side-effect of opioid use for pain 
relief or abuse for euphoria.   
 
Methylnaltrexone is an antagonist at opioid µ-receptors.  It can be administered orally, 
subcutaneously or intravenously.  Methylnaltrexone does not cross the blood-brain barrier.  
Methynaltrexone antagonises the ability of opioids to cause constipation but, because it does 
not cross the blood-brain barrier. it does not antagonise the centrally-mediated analgesic 
effect of morphine.  Methlynatrexone is used in combination with morphine to give pain 
relief (due to the morphine) without the constipation (morphine-induced constipation 
prevented by methylnaltrexone). 
 
 
16.4. DRUGS FOR INFLAMMATORY BOWEL DISEASE 
 
Inflammatory bowel disease is distinct from irritable bowel disease/syndrome.  
Inflammatory bowel disease is chronic inflammation of small and large intestines, usually of 
unknown aetiology (cause).   
 
Inflammatory bowel disease includes Crohn’s disease, which can affect both the small and 
large bowel.  In Crohn’s disease, the inflammation is focal (localised) but can affect all layers 
of the bowel.  The symptoms of Crohn’s disease are severe abdominal pain, diarrhea (which 
may contain blood), vomiting, and weight loss. 
 
Inflammatory bowel disease also includes ulcerative colitis (ulcers in the colon), which is 
confined to the colon and characterized by chronic, superficial inflammation.  Ulcerative 
colitis always involves distal colon and extends continuously for a variable length 
proximally.   
 
As the inflammation of inflammatory bowel disease is severe, it is not overcome by using a 
NSAID.  Thus, stronger anti-inflammatory agents are required. 
 
16.4.1 Mesalazine 
Drugs related to the salicylates (i.e. aspirin), 5-aminosalicylates, such as mesalazine, are 
used in the treatment of inflammatory bowel disease.  Mesalazine inhibits both the 
cyclooxygenase pathway and lipooxygenase pathway, whereas the NSAIDs only inhibit the 
cyclooxygenase pathway.  Thus, mesalazine inhibits the production of prostaglandins in the 
cyclooxygenase pathway, which have a relatively minor effect in inflammation.  Mesalazine 
also inhibit the lipooxygenase pathway to reduce the levels of leukotrienes, which have a 
major role in inflammation.   
 
Mesalazine is effective in mild or moderate active ulcerative colitis, but is a less successful 
treatment in severe ulcerative colitis.  Mesalazine is also less useful in Crohn’s disease.  
Mesalazine alone is absorbed before the colon, which reduces its effectiveness.  Thus, 
mesalazine is used in enteric coated tablets to reduce any absorption from the stomach. 
 
 16.4.2 Glucocorticoids 
Another major treatment for inflammatory bowel disease is the glucocorticoids.  In addition 
to inhibiting the production of prostaglandins and leukotrienes by inhibiting phospholipase 
A2 (as discussed in chapter 17.3), glucocorticoids have inhibitory effects on other 
components of inflammation, such as histamine, cytokines, and adhesion molecules.  
Adhesion molecules are required for white blood cells to adhere to the site of inflammation.  
Prednisone is an example of a glucocorticoid, which inhibits all these components of 
inflammation.  Oral prednisone is the standard treatment for acute severe exacerbations of 
inflammatory bowel disease.  Indeed, prednisone gives remission in most patients with 
ulcerative colitis and active Crohn’s disease.  
 
The main problem with glucocorticoids, such as prednisone, is systemic circulation leads to 
increasing and more severe side effects with time.  Thus only short courses of treatment 
should be used.  With prolonged systemic treatment, prednisone causes the side effects of 
hypertension, hyperglycemia, an increased susceptibility to infection, osteoporosis, 
myopathy, behavioural disturbances, cataracts and more!  Clearly, it is best to avoid long 
treatment with prednisone.  Thus, prednisone is reserved for acute severe exacerbations of 
inflammatory bowel disease.   
 
An alternative approach, if long term treatment with glucocorticoids is necessary is to use a 
glucocorticoid with extensive first pass liver metabolism to avoid some of the systemic side 
effects e.g. budesonide.   
 
The weak glucocorticoid hydocorticosterone is used in enemas for a local effect in 
inflammation limited to the rectum (proctitis). 
 
16.4.3 Infliximab 
The cytokine tumour necrosis factor-alpha (TNFα) has major role in Crohn’s disease and 
ulcerative colitis.  Thus, inhibitors of TNFα are used in the treatment of Crohn’s disease and 
ulcerative colitis.  Infliximab is an antibody to TNFα i.e. it binds to TNFα and inactivates it.  
Infliximab is used in the treatment of moderate-to-severe Crohn’s disease and moderate-to-
severe ulcerative colitis.  Infliximab is not active after oral administration and is given 
intravenously every 8 weeks to people with Crohn’s disease or ulcerative colitis. 
 
